US 11,939,383 B2
B7-H4 antibodies and methods and use thereof
Charles Kaplan, South San Francisco, CA (US); Alessandro Palumbo, South San Francisco, CA (US); Kathy Miller, South San Francisco, CA (US); Hangil Park, South San Francisco, CA (US); Nerissa Mendoza, South San Francisco, CA (US); and Majid Ghoddusi, South San Francisco, CA (US)
Assigned to FIVE PRIME THERAPEUTICS, INC., South San Francisco, CA (US)
Filed by Five Prime Therapeutics, Inc., South San Francisco, CA (US)
Filed on Aug. 28, 2020, as Appl. No. 17/006,670.
Application 17/006,670 is a continuation of application No. PCT/US2019/020189, filed on Mar. 1, 2019.
Claims priority of provisional application 62/637,740, filed on Mar. 2, 2018.
Prior Publication US 2021/0079096 A1, Mar. 18, 2021
Int. Cl. C07K 16/18 (2006.01); A61K 39/00 (2006.01); A61K 39/395 (2006.01); A61P 35/00 (2006.01); C07K 16/28 (2006.01); G01N 33/574 (2006.01)
CPC C07K 16/2827 (2013.01) [G01N 33/57492 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); G01N 2333/70532 (2013.01)] 17 Claims
OG exemplary drawing
 
1. An isolated antibody or antigen-binding fragment thereof that specifically binds to human B7-H4, comprising a heavy chain variable region (VH) complementarity determining region (CDR) 1 comprising the amino acid sequence of SEQ ID NO:22, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:23, a VH CDR3 comprising the amino acid sequence of SEQ ID NO:24, a light chain variable region (VL) CDR1 comprising the amino acid sequence of SEQ ID NO:25, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:26, 27, or 28, and a VL CDR3 sequence comprising the amino acid sequence of SEQ ID NO:29.